Previous 10 | Next 10 |
Vaxart (VXRT) has signed an exclusive worldwide licensing agreement with Altesa Biosciences to develop and commercialize patented formulation of Vapendavir in a deal worth as much as $130M.Share up more than 5% premarket.Vaxart is eligible to receive up to $130M in development and c...
Milestone payments up to $130 million and royalties for global Vapendavir sales Vapendavir has demonstrated activity against a broad spectrum of enteroviruses SOUTH SAN FRANCISCO, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stag...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While California-based biotech company Vaxart (NASDAQ: VXRT ) isn’t the only vaccine maker out there, VXRT stock traders should know that this company is like no other. Source: Photo courtesy of Vaxart, Inc...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart (NASDAQ: VXRT ) is a California-based biotech company that’s developing vaccines. Like so many other biotech namess over the past year, that also includes taking on Covid-19. And, also like many of these...
Alexey Koza/iStock via Getty Images Jefferies has begun the coverage of Vaxart ([[VXRT]] +5.8%) with a buy recommendation noting that its vaccine platform allows the development of oral vaccines for prophylaxis from infectious diseases. The price target at $13.00 per share implies a premium o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors in Vaxart (NASDAQ: VXRT ) and VXRT stock have seen some pretty impressive volatility of late. Indeed, this stock rose as much as 12% this morning on heavier-than-normal volume. Source: Ascannio...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips When I last wrote about Vaxart (NASDAQ: VXRT ) last month I indicated that I felt that the biotech company was not worth more than about $1 per share. As of June 16, VXRT stock was at $7.67, or $1.00 higher than when ...
Shares of several COVID-19 vaccine makers were sinking on Tuesday morning. Dynavax Technologies (NASDAQ: DVAX) stock was down 6.3% as of 11:26 a.m. EDT, while shares of Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) were falling 7.8% and 10.6%, respectively. No...
On June 11, Vaxart (NASDAQ: VXRT) stock skyrocketed 22% after Piper Sandler analyst Yasmeen Rahimi initiated coverage of the company with a price target of $18. That represents an upside of 151% from that day's open. In setting the price target, the analyst cited the validation ...
5 Trending Biotech Stocks To Watch In The Stock Market Now You can’t deny that biotech stocks have and continue to make headlines throughout the globe over the past year. After all, this section of the stock market contains the most active stocks today, for a good rea...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...